Ensysce Biosciences
ENSC
12 hedge funds and large institutions have $231K invested in Ensysce Biosciences in 2023 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 2 closing their positions.
150% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 2
33% more funds holding
Funds holding: 9 → 12 (+3)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
7.98% less ownership
Funds ownership: 13.84% → 5.86% (-8%)
82% less capital inflows, than outflows
Capital inflows: $95.4K | Capital outflows: $524K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$36.2K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$31.1K |
| 3 |
Two Sigma Securities
New York
|
+$27.6K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$284 |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$114 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$426K |
| 2 |
Anson Funds Management
Dallas,
Texas
|
-$65.3K |
| 3 |
GSA Capital Partners
London,
United Kingdom
|
-$32K |
ENSC Hedge Fund Activity: Q3 2023 in Review
12 of the 6,316 institutional investors tracked by Wall St. Rank reported a position in Ensysce Biosciences (ENSC) for Q3 2023, worth a combined $231K — down 68% from $714K a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new ENSC positions and 2 closed out — a net gain of 3 holders — while 1 added to existing stakes and 1 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $36.2K. The largest seller was Sabby Management, cutting an estimated $426K.
- 12 institutional investors held Ensysce Biosciences (ENSC) as of Q3 2023, up from 9 in Q2 2023.
- Funds reported $231K of Ensysce Biosciences stock for Q3 2023, down 68% quarter-over-quarter.
- 5 funds opened new Ensysce Biosciences positions in Q3 2023 and 2 closed out, a net change of +3 holders.
- The largest Ensysce Biosciences buyer in Q3 2023 was Citadel Advisors, an estimated $36.2K added.
- The largest Ensysce Biosciences seller in Q3 2023 was Sabby Management, an estimated $426K sold.
Based on aggregated 13F filings for Q3 2023.